<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Granular parakeratosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Granular parakeratosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Granular parakeratosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jami L Miller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cindy Owen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 01, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3750373071">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Granular parakeratosis (GP) is an uncommon, usually pruritic, benign dermatosis found most often in the axillae or other intertriginous areas. The majority of authors describe GP as a specific disease entity, but it has also been proposed that the term "granular parakeratosis" be used to describe the distinctive histopathologic characteristics (parakeratosis and retention of keratohyalin granules in the stratum corneum  (
         <a class="graphic graphic_picture graphicRef109373 graphicRef109374" href="/z/d/graphic/109373.html" rel="external">
          picture 1A-B
         </a>
         )) rather than to describe a specific dermatosis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Other terms that have been used to refer to GP include "hyperkeratotic flexural erythema" and the colloquial term "zombie patch." (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p>
         That GP is a true clinical entity rather than a reactive histologic pattern is supported by its unique clinical appearance; it demonstrates erythematous to brown, hyperkeratotic papules that may coalesce into plaques  (
         <a class="graphic graphic_picture graphicRef108741 graphicRef108742 graphicRef73591" href="/z/d/graphic/108741.html" rel="external">
          picture 2A-C
         </a>
         ). Since the initial description of GP involving the axilla in 1991 [
         <a href="#rid2">
          2
         </a>
         ], it has been reported in other intertriginous areas, including inframammary, inguinal, genital, and perianal skin; beneath the abdominal pannus; and in nonintertriginous sites, particularly on the lumbosacral area.
        </p>
        <p>
         The clinical features, diagnosis, and management of GP will be reviewed here.
        </p>
        <p class="headingAnchor" id="H3834398079">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         GP appears to be uncommon but is likely underreported. In a retrospective study of over 360,000 cutaneous biopsy specimens submitted to a dermatopathology institute, 0.005 percent of specimens confirmed a diagnosis of GP [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         GP has been reported more often in women than in men [
         <a href="#rid4">
          4
         </a>
         ]; a higher likelihood for women to seek treatment may be a contributing factor. Most reports describe it in persons over 40 years of age, although all age groups may be affected, including children and infants [
         <a href="#rid4">
          4
         </a>
         ]. There is at least one report of congenital GP [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4097118245">
         <span class="h1">
          ETIOLOGY AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of GP is unknown. It appears to be a reactive process in the skin [
         <a href="#rid1">
          1
         </a>
         ], and most reports elaborate associations with skin maceration (due to occlusion [
         <a href="#rid2">
          2
         </a>
         ], warm environments [
         <a href="#rid6">
          6
         </a>
         ], sweating, obesity, repeated washing [
         <a href="#rid7">
          7
         </a>
         ]) or skin irritation from external agents (eg, antiperspirants, deodorants, and
         <a class="drug drug_general" data-topicid="10326" href="/z/d/drug information/10326.html" rel="external">
          zinc oxide
         </a>
         ). Exposure to benzalkonium chloride, a preservative and antiseptic used in many products including laundry rinses, personal hygiene wipes, medical solutions, and more, has been proposed as an inciting factor in case reports [
         <a href="#rid8">
          8,9
         </a>
         ]. Development of GP following the use of a depilatory cream has also been reported [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The pathogenic mechanism of GP most likely involves a stimulus (either external or internal) that triggers a failure of normal keratinocyte maturation in the stratum granulosum. This results in the retention of nuclei in the upper layers of the stratum corneum (ie, parakeratosis). There is also a failure to process profilaggrin into filaggrin that may inhibit the normal disappearance of keratohyalin granules of the stratum granulosum as the keratinocytes mature and flatten to become the stratum corneum [
         <a href="#rid11">
          11
         </a>
         ]. Increased epidermal turnover may lead to epidermal hypertrophy and thickening of the stratum corneum [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The histologic changes of GP have been demonstrated in mouse skin treated daily with aluminum chloride 20% spray, suggesting a potential pathogenic role for topical aluminum chloride [
         <a href="#rid13">
          13
         </a>
         ]. Cytochrome C and cleaved-caspase 3, both apoptosis-inducing factors, were upregulated in the granular layer of affected mouse skin. The authors postulated that aluminum chloride-induced apoptosis may contribute to manifestations of GP through interruption of keratinization and the inhibition of processing of profilaggrin to filaggrin. Inhibition of caspase 3 prevented the GP-like skin changes. (See
         <a class="local">
          'Histopathology'
         </a>
         below.)
        </p>
        <p>
         GP has also occurred without an obvious external insult and has occurred congenitally; it is proposed that these cases may be due to an acquired disorder of cornification [
         <a href="#rid5">
          5,11
         </a>
         ]. In support of this theory, mice deficient in caspase 14, a protease that is important in forming a functional skin barrier, are more prone to the development of parakeratosis than wild-type mice [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2643219239">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary lesion of GP is the hyperkeratotic papule. Papules may be discrete but usually coalesce into well-demarcated plaques that can have satellite papules. Reticular patterns may also occur. The papules or plaques are usually erythematous, red-brown, or brown and may become violaceous and lichenified if scratched aggressively  (
         <a class="graphic graphic_picture graphicRef108741 graphicRef108742 graphicRef73591" href="/z/d/graphic/108741.html" rel="external">
          picture 2A-C
         </a>
         ). A follicular variant has been reported [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         GP is typically found in intertriginous areas, such as the axillae (most common), inframammary folds, inguinal creases, beneath the abdominal pannus, or on the vulva, penis, or perianal skin. In infants, it may occur in the diaper area, especially in sites of friction or pressure. Occasionally, nonintertriginous skin is involved, such as the lumbosacral area, neck [
         <a href="#rid16">
          16
         </a>
         ], or face [
         <a href="#rid17">
          17
         </a>
         ]. It may be unilateral or bilateral and may occur in multiple locations [
         <a href="#rid4">
          4,18
         </a>
         ].
        </p>
        <p>
         GP is usually pruritic and may be malodorous. Due to the common location in the skin folds, the plaques may become macerated, eroded, or fissured, which may cause burning or pain. Heat and moisture (eg, warm, humid environments) may be aggravating factors.
        </p>
        <p>
         GP generally is not associated with other diseases, but clinical findings of GP have been reported in patients receiving chemotherapy for breast [
         <a href="#rid19">
          19
         </a>
         ] and ovarian carcinomas [
         <a href="#rid20">
          20
         </a>
         ]. It has also occurred in a patient with dermatomyositis [
         <a href="#rid21">
          21
         </a>
         ]. Whether these patients experienced significant perspiration prior to the appearance of GP is not mentioned. One publication reports seven cases of infantile GP in which five infants also had atopic dermatitis [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1899858232">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin biopsies of GP show hyperkeratosis and compact parakeratosis within the stratum corneum. Cells in the upper skin strata contain basophilic keratohyalin granules, a finding that is the hallmark of the disease  (
         <a class="graphic graphic_picture graphicRef109373 graphicRef109374" href="/z/d/graphic/109373.html" rel="external">
          picture 1A-B
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. The epidermis is most often thickened in a psoriasiform or acanthotic pattern with or without papillomatosis. A low-grade lymphohistiocytic infiltrate also may be present [
         <a href="#rid2">
          2
         </a>
         ]. Variants of GP in which the characteristic histologic findings are localized to the follicular infundibula or the eccrine ostia have been reported [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         Electron microscopy shows stellate or round keratohyalin bodies in the granular layer. Fungal and bacterial stains are negative. Direct immunofluorescence is negative.
        </p>
        <p>
         The histopathologic finding of GP may occur in other disease entities. Incidental GP has been detected in biopsy specimens of dermatomyositis, cutaneous dermatophyte infections [
         <a href="#rid23">
          23
         </a>
         ], and molluscum contagiosum [
         <a href="#rid24">
          24
         </a>
         ], as well as in cutaneous neoplasms, including actinic keratosis, keratoacanthomas, and squamous cell carcinomas
         <sup>
         </sup>
         [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3358601865">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         An eruption with clinical features consistent with GP (well-demarcated, red or brown, hyperkeratotic papules or plaques on intertriginous skin) can strongly suggest the diagnosis. Because the primary diagnostic criteria are histopathologic, a skin biopsy demonstrating parakeratosis and retention of keratohyalin granules in the stratum corneum is usually needed for confirmation. A punch biopsy or shave biopsy is sufficient. (See
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques"
         </a>
         .)
        </p>
        <p>
         The findings of a small case series suggest that a superficial skin scraping may be a less invasive alternative for confirming the diagnosis in young children with clinical features of GP. In a series in which six of seven infants with clinical findings suggestive of GP had scrapings of the stratum corneum performed and stained with May-Grünwald Giemsa and Papanicolaou stains, cytologic examination revealed cells with keratohyalin granules and retained nuclei in all six patients [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3360071394">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of GP is broad and includes a variety of other disorders with a predilection for intertriginous skin. In particular, cases in which hyperkeratosis is less prominent may be mistaken for common inflammatory or infectious disorders such as inverse psoriasis, intertrigo, dermatophyte infections, and erythrasma. Inverse psoriasis plaques often exhibit a shiny appearance. A potassium hydroxide preparation will quickly identify candidal intertrigo and dermatophyte infections. Coral-red fluorescence upon illumination of involved skin with a Wood's lamp identifies erythrasma. (See
         <a class="medical medical_review" href="/z/d/html/115364.html" rel="external">
          "Approach to the patient with an intertriginous skin disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5664.html" rel="external">
          "Psoriasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Inverse (intertriginous) psoriasis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4031.html" rel="external">
          "Erythrasma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">
          "Intertrigo"
         </a>
         .)
        </p>
        <p>
         Disorders in the differential diagnosis include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acanthosis nigricans (particularly for lichenified GP or GP in dark skin)  (
         <a class="graphic graphic_picture graphicRef66384" href="/z/d/graphic/66384.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Folliculitis  (
         <a class="graphic graphic_picture graphicRef68351" href="/z/d/graphic/68351.html" rel="external">
          picture 4
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythrasma  (
         <a class="graphic graphic_picture graphicRef80242" href="/z/d/graphic/80242.html" rel="external">
          picture 5
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seborrheic dermatitis  (
         <a class="graphic graphic_picture graphicRef53407 graphicRef73813" href="/z/d/graphic/53407.html" rel="external">
          picture 6A-B
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fox-Fordyce disease (apocrine miliaria)  (
         <a class="graphic graphic_picture graphicRef105574" href="/z/d/graphic/105574.html" rel="external">
          picture 7
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eccrine miliaria (particularly miliaria rubra  (
         <a class="graphic graphic_picture graphicRef102848" href="/z/d/graphic/102848.html" rel="external">
          picture 8
         </a>
         ))
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hidradenitis suppurativa  (
         <a class="graphic graphic_picture graphicRef114609" href="/z/d/graphic/114609.html" rel="external">
          picture 9
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contact dermatitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inverse psoriasis  (
         <a class="graphic graphic_picture graphicRef99438" href="/z/d/graphic/99438.html" rel="external">
          picture 10
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intertrigo  (
         <a class="graphic graphic_picture graphicRef99894" href="/z/d/graphic/99894.html" rel="external">
          picture 11
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axillary syringomas
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hailey-Hailey disease  (
         <a class="graphic graphic_picture graphicRef76004" href="/z/d/graphic/76004.html" rel="external">
          picture 12
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bowen's disease  (
         <a class="graphic graphic_picture graphicRef82358" href="/z/d/graphic/82358.html" rel="external">
          picture 13
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Verrucae
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Darier disease  (
         <a class="graphic graphic_picture graphicRef86186" href="/z/d/graphic/86186.html" rel="external">
          picture 14
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extramammary Paget disease  (
         <a class="graphic graphic_picture graphicRef95067" href="/z/d/graphic/95067.html" rel="external">
          picture 15
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dermatophyte infection  (
         <a class="graphic graphic_picture graphicRef71067" href="/z/d/graphic/71067.html" rel="external">
          picture 16
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Epidermal nevus  (
         <a class="graphic graphic_picture graphicRef86582" href="/z/d/graphic/86582.html" rel="external">
          picture 17
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inverse lichen planus  (
         <a class="graphic graphic_picture graphicRef90122" href="/z/d/graphic/90122.html" rel="external">
          picture 18
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pemphigus vegetans  (
         <a class="graphic graphic_picture graphicRef60187" href="/z/d/graphic/60187.html" rel="external">
          picture 19
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dowling-Degos disease  (
         <a class="graphic graphic_picture graphicRef77681" href="/z/d/graphic/77681.html" rel="external">
          picture 20
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         In infants and young children, GP often involves the diaper area. The differential diagnosis for these patients should also include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acrodermatitis enteropathica  (
         <a class="graphic graphic_picture graphicRef71329" href="/z/d/graphic/71329.html" rel="external">
          picture 21
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Langerhans cell histiocytosis  (
         <a class="graphic graphic_picture graphicRef57722" href="/z/d/graphic/57722.html" rel="external">
          picture 22
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3615846834">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         GP follows a variable course. Spontaneous resolution has been described, but how often this happens or how long it takes have not been elucidated. Conversely, the clinical manifestations may wax and wane or resolve for a period of time followed by recurrence. Cases persisting for more than 20 years have been reported [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4091876446">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many treatments have been used for GP, with variable success [
         <a href="#rid4">
          4
         </a>
         ].
         <strong>
         </strong>
         Elimination of possible causative factors is the mainstay of management, but the eruption may persist after potential exposures have been removed.
        </p>
        <p class="headingAnchor" id="H4259070572">
         <span class="h2">
          Elimination of exacerbating factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical experience suggests that measures such as changing the type of deodorant or antiperspirant, avoiding other potentially irritating topical agents, and minimizing moisture in affected areas can resolve some cases of GP [
         <a href="#rid9">
          9
         </a>
         ]. The efficacy of these interventions has not been evaluated in clinical studies. There is a report of inframammary GP that was successfully treated with reduction mammoplasty [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         We typically advise patients with axillary involvement to switch from a solid deodorant or antiperspirant to a gel or spray product to minimize skin maceration as well as to limit use of deodorants and antiperspirants as much as is acceptable. We also encourage patients to avoid applying fragranced products to affected areas. Avoidance of shaving may also be beneficial. These interventions should be implemented for at least two weeks for an adequate therapeutic trial.
        </p>
        <p class="headingAnchor" id="H1456603884">
         <span class="h2">
          Medical interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although GP can be self-limited,
         <strong>
         </strong>
         treatment may be initiated in an attempt to accelerate resolution. Treatments for GP have included topical agents, systemic agents, and procedural interventions. However, efficacy data are limited to case reports and small case series, preventing definitive conclusions about the efficacy of these interventions [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Topical therapies are generally used as first-line treatment. Topical agents reported to improve GP include topical corticosteroids (alone or in combination with topical antifungal agents), topical vitamin D analogues, and
         <a class="drug drug_general" data-topicid="10014" href="/z/d/drug information/10014.html" rel="external">
          topical tretinoin
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – Responses of GP to low-potency to high-potency topical corticosteroids alone or in combination with topical antifungal agents have been reported [
         <a href="#rid18">
          18,28-31
         </a>
         ]. Because of a relatively low risk for serious side effects, low-potency topical corticosteroids such as
         <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">
          hydrocortisone
         </a>
         1 to 2.5% cream or lotion are generally the first line of treatment  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ). Responses may be evident within a few days to a few weeks. In a series of three patients, twice-daily application of the high-potency topical corticosteroid
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         dipropionate alone or in combination with
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         1% was associated with resolution of GP within 10 days [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Therapy with topical corticosteroids of any potency carries risk of cutaneous atrophy and striae in the axillae and other skin fold areas. Treatment with corticosteroids should be discontinued as soon as the clinical manifestations resolve or after a maximum of 7 to 10 days for group 1 to 4 topical corticosteroids and a maximum of four weeks for group 5 to 7 topical corticosteroids  (
         <a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The reason topical corticosteroids may be beneficial is unclear. An effect of glucocorticoids on profilaggrin expression and processing has been postulated [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical vitamin D analogues
         </strong>
         – Treatment with topical vitamin D analogues has been associated with improvement in GP in case reports [
         <a href="#rid10">
          10,32,33
         </a>
         ]. Twice-daily treatment with topical
         <a class="drug drug_general" data-topicid="9183" href="/z/d/drug information/9183.html" rel="external">
          calcitriol
         </a>
         ointment (3 mcg/g) has been associated with complete resolution of GP within 10 days in one patient [
         <a href="#rid34">
          34
         </a>
         ]. A beneficial effect of vitamin D analogues may involve inhibition of keratinocyte proliferation and the promotion of terminal differentiation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical retinoids
         </strong>
         – A case report describes complete clearance of axillary GP within five days during treatment with tretinoin 0.025% cream once daily [
         <a href="#rid35">
          35
         </a>
         ]. The authors proposed that benefit may have resulted from the effects of tretinoin on filaggrin expression or keratolytic effects of tretinoin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Skin irritation is a potential side effect that may require cessation of retinoid therapy. Because of the potential for irritation, avoiding treatment in the groin or perianal areas is prudent.
        </p>
        <p>
        </p>
        <p>
         Other topical anti-inflammatory agents may also be useful but have not been specifically reported in the treatment of GP. Topical calcineurin inhibitors applied twice daily may be a good alternative to topical corticosteroids as they do not induce atrophy of the skin. Topical antibiotics such as
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         may also be helpful, likely due to both anti-inflammatory and antibacterial action.
        </p>
        <p>
         Other interventions may be useful for GP refractory to topical therapy. Several case reports document benefit of various oral antibiotics, including amoxicillin-clavulanic acid and
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         [
         <a href="#rid36">
          36,37
         </a>
         ]. Two or three weeks of treatment with oral
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         (40 mg per day) appeared to resolve GP in a patient who did not respond to mild topical corticosteroids and
         <a class="drug drug_general" data-topicid="9665" href="/z/d/drug information/9665.html" rel="external">
          tazarotene
         </a>
         [
         <a href="#rid38">
          38
         </a>
         ]. Oral isotretinoin therapy was also associated with improvement in a patient who had not improved during treatment with topical
         <a class="drug drug_general" data-topicid="8458" href="/z/d/drug information/8458.html" rel="external">
          fluocinolone
         </a>
         and oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         [
         <a href="#rid39">
          39
         </a>
         ]. Rapid resolution of GP has also been reported in a woman treated with a combination of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         (100 mg twice daily), topical
         <a class="drug drug_general" data-topicid="9331" href="/z/d/drug information/9331.html" rel="external">
          desonide
         </a>
         , and topical
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Another report describes rapid resolution of axillary GP after botulinum toxin injection [
         <a href="#rid40">
          40
         </a>
         ]. Ablative treatment with an erbium:yttrium aluminum garnet and carbon dioxide laser led to clearance of GP in one patient, albeit with residual scarring [
         <a href="#rid41">
          41
         </a>
         ]. Other destructive measures may also be helpful for small lesions, such as cryotherapy or electrosurgery. Short courses of oral glucocorticoids may yield relief from severe inflammation and pruritus.
        </p>
        <p class="headingAnchor" id="H1266188986">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Granular parakeratosis (GP; also known as hyperkeratotic flexural erythema) is an uncommon cutaneous disorder that typically manifests as hyperkeratotic papules or plaques on intertriginous skin. GP is distinguished by its characteristic histopathologic findings of retained keratohyalin granules in the stratum corneum and parakeratosis  (
         <a class="graphic graphic_picture graphicRef109373 graphicRef109374" href="/z/d/graphic/109373.html" rel="external">
          picture 1A-B
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – GP appears to occur most frequently in adult women but may occur at any age, including infancy. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology and pathogenesis
         </strong>
         – The etiology of GP is unclear. Development is frequently associated with maceration or irritation of the affected skin. These might trigger defective keratinocyte maturation, resulting in the characteristic clinical and histopathologic findings. GP may also occur in the absence of such factors. (See
         <a class="local">
          'Etiology and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – GP most commonly presents as pruritic, red to brown, hyperkeratotic papules that may coalesce into well-demarcated plaques on intertriginous skin  (
         <a class="graphic graphic_picture graphicRef108741 graphicRef108742 graphicRef73591" href="/z/d/graphic/108741.html" rel="external">
          picture 2A-C
         </a>
         ). The axilla is the most common site of involvement. GP has also been reported on nonintertriginous skin. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – A diagnosis of GP may be suspected based upon the clinical findings. A skin biopsy demonstrating parakeratosis and retained keratohyalin granules in the stratum corneum confirms the diagnosis. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Course
         </strong>
         – The clinical course of GP varies. It is likely that many cases spontaneously resolve. (See
         <a class="local">
          'Natural history'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Avoidance of potential exacerbating factors is the mainstay of therapy for GP. Data on the efficacy of medical therapies are limited. We suggest topical therapies rather than systemic or procedural interventions as first-line medical treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Topical therapies that may be useful include corticosteroids, vitamin D analogues, and tretinoin. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Ding CY, Liu H, Khachemoune A. Granular Parakeratosis: A Comprehensive Review and a Critical Reappraisal. Am J Clin Dermatol 2015; 16:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Northcutt AD, Nelson DM, Tschen JA. Axillary granular parakeratosis. J Am Acad Dermatol 1991; 24:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheinfeld NS, Mones J. Granular parakeratosis: pathologic and clinical correlation of 18 cases of granular parakeratosis. J Am Acad Dermatol 2005; 52:863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ip KH, Li A. Clinical features, histology, and treatment outcomes of granular parakeratosis: a systematic review. Int J Dermatol 2022; 61:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leclerc-Mercier S, Prost-Squarcioni C, Hamel-Teillac D, Fraitag S. A case of congenital granular parakeratosis. Am J Dermatopathol 2011; 33:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodríguez G. [Axillary granular parakeratosis]. Biomedica 2002; 22:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neri I, Patrizi A, Guerrini V, Fanti PA. Granular parakeratosis in a child. Dermatology 2003; 206:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson AJ, Foster RS, Halbert AR, et al. Granular parakeratosis induced by benzalkonium chloride exposure from laundry rinse aids. Australas J Dermatol 2017; 58:e138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dear K, Gan D, Stavrakoglou A, et al. Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry sanitizers containing benzalkonium chloride. Clin Exp Dermatol 2022; 47:2196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samrao A, Reis M, Niedt G, Rudikoff D. Granular parakeratosis: response to calcipotriene and brief review of current therapeutic options. Skinmed 2010; 8:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metze D, Rütten A. Granular parakeratosis - a unique acquired disorder of keratinization. J Cutan Pathol 1999; 26:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodhouse JG, Bergfeld W. Granular parakeratosis. Pediatr Dermatol 2004; 21:684.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii M, Kishibe M, Honma M, et al. Aluminum Chloride-Induced Apoptosis Leads to Keratinization Arrest and Granular Parakeratosis. Am J Dermatopathol 2020; 42:756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoste E, Denecker G, Gilbert B, et al. Caspase-14-deficient mice are more prone to the development of parakeratosis. J Invest Dermatol 2013; 133:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resnik KS, DiLeonardo M. Follicular granular parakeratosis. Am J Dermatopathol 2003; 25:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JH, Lee HM, Noh TK, et al. Granular parakeratosis of eccrine ostia. Ann Dermatol 2012; 24:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi R, Taneja A. Granular parakeratosis presenting with facial keratotic papules. Indian J Dermatol Venereol Leprol 2008; 74:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burford C. Granular parakeratosis of multiple intertriginous areas. Australas J Dermatol 2008; 49:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace CA, Pichardo RO, Yosipovitch G, et al. Granular parakeratosis: a case report and literature review. J Cutan Pathol 2003; 30:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaconelli L, Doebelin B, Kanitakis J, et al. Granular parakeratosis in a patient treated with liposomal doxorubicin for ovarian carcinoma. J Am Acad Dermatol 2008; 58:S84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva L, Pimentel BV, Sousa JT, Viana IF. Granular parakeratosis in a case of dermatomyositis. Indian J Dermatol Venereol Leprol 2023; 89:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akkaya AD, Oram Y, Aydın Ö. Infantile granular parakeratosis: cytologic examination of superficial scrapings as an aid to diagnosis. Pediatr Dermatol 2015; 32:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resnik KS, Kantor GR, DiLeonardo M. Dermatophyte-related granular parakeratosis. Am J Dermatopathol 2004; 26:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pock L, Cermáková A, Zipfelová J, Hercogová J. Incidental granular parakeratosis associated with molluscum contagiosum. Am J Dermatopathol 2005; 27:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Resnik KS, DiLeonardo M. Incidental granular parakeratotic cornification in carcinomas. Am J Dermatopathol 2007; 29:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy IS, Swarnalata G, Mody T. Intertriginous granular parakeratosis persisting for 20 years. Indian J Dermatol Venereol Leprol 2008; 74:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson G, Lien MH, Messina JL, et al. Submammary Granular Parakeratosis Treated With Mastopexy. J Drugs Dermatol 2017; 16:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chamberlain AJ, Tam MM. Intertriginous granular parakeratosis responsive to potent topical corticosteroids. Clin Exp Dermatol 2003; 28:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehregan DA, Thomas JE, Mehregan DR. Intertriginous granular parakeratosis. J Am Acad Dermatol 1998; 39:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezra N, Karunasiri D, Chiu MW. Unilateral pruritic axillary rash: axillary granular parakeratosis. Arch Dermatol 2008; 144:1651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehregan DA, Vandersteen P, Sikorski L, Mehregan DR. Axillary granular parakeratosis. J Am Acad Dermatol 1995; 33:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demitsu T, Nakamura S, Takazawa M, et al. Axillary granular parakeratosis with osmidrosis successfully treated with topical maxacalcitol. J Dermatol 2019; 46:e155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbina F, Sudy E, Misad C. Two episodes of axillary granular parakeratosis triggered by different causes: case report. Acta Dermatovenerol Croat 2012; 20:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel U, Patel T, Skinner RB Jr. Resolution of granular parakeratosis with topical calcitriol. Arch Dermatol 2011; 147:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown SK, Heilman ER. Granular parakeratosis: resolution with topical tretinoin. J Am Acad Dermatol 2002; 47:S279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herat A, Gonzalez Matheus G, Kumarasinghe SP. Hyperkeratotic flexural erythema/granular parakeratosis responding to doxycycline. Australas J Dermatol 2022; 63:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumarasinghe SPW, Chandran V, Raby E, Wood B. Hyperkeratotic flexural erythema responding to amoxicillin-clavulanic acid therapy: Report of four cases. Australas J Dermatol 2019; 60:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compton AK, Jackson JM. Isotretinoin as a treatment for axillary granular parakeratosis. Cutis 2007; 80:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster CG, Resnik KS, Webster GF. Axillary granular parakeratosis: response to isotretinoin. J Am Acad Dermatol 1997; 37:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravitskiy L, Heymann WR. Botulinum toxin-induced resolution of axillary granular parakeratosis. Skinmed 2005; 4:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laimer M, Emberger M, Brunasso AM, et al. Laser for the treatment of granular parakeratosis. Dermatol Surg 2009; 35:297.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 99982 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26242230" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Granular Parakeratosis: A Comprehensive Review and a Critical Reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2033126" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Axillary granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15858479" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Granular parakeratosis: pathologic and clinical correlation of 18 cases of granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35094385" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical features, histology, and treatment outcomes of granular parakeratosis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21587032" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : A case of congenital granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12596449" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : [Axillary granular parakeratosis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592091" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Granular parakeratosis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27641714" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Granular parakeratosis induced by benzalkonium chloride exposure from laundry rinse aids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36164686" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Hyperkeratotic flexural erythema (more commonly known as granular parakeratosis) with use of laundry sanitizers containing benzalkonium chloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21413654" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Granular parakeratosis: response to calcipotriene and brief review of current therapeutic options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487291" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Granular parakeratosis - a unique acquired disorder of keratinization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15575860" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567135" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Aluminum Chloride-Induced Apoptosis Leads to Keratinization Arrest and Granular Parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23014340" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Caspase-14-deficient mice are more prone to the development of parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501292" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Follicular granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22577273" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Granular parakeratosis of eccrine ostia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18187827" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Granular parakeratosis presenting with facial keratotic papules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18186846" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Granular parakeratosis of multiple intertriginous areas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12753175" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Granular parakeratosis: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18489055" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Granular parakeratosis in a patient treated with liposomal doxorubicin for ovarian carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34379961" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Granular parakeratosis in a case of dermatomyositis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25660113" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Infantile granular parakeratosis: cytologic examination of superficial scrapings as an aid to diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14726826" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dermatophyte-related granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15900134" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Incidental granular parakeratosis associated with molluscum contagiosum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519624" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Incidental granular parakeratotic cornification in carcinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18797082" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Intertriginous granular parakeratosis persisting for 20 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28809996" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Submammary Granular Parakeratosis Treated With Mastopexy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558631" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Intertriginous granular parakeratosis responsive to potent topical corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738790" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intertriginous granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075156" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Unilateral pruritic axillary rash: axillary granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7615889" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Axillary granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30575121" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Axillary granular parakeratosis with osmidrosis successfully treated with topical maxacalcitol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22726284" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Two episodes of axillary granular parakeratosis triggered by different causes: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844474" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Resolution of granular parakeratosis with topical calcitriol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12399751" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Granular parakeratosis: resolution with topical tretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35535765" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Hyperkeratotic flexural erythema/granular parakeratosis responding to doxycycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31049927" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hyperkeratotic flexural erythema responding to amoxicillin-clavulanic acid therapy: Report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17725066" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Isotretinoin as a treatment for axillary granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9366832" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Axillary granular parakeratosis: response to isotretinoin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15785142" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Botulinum toxin-induced resolution of axillary granular parakeratosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19215276" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Laser for the treatment of granular parakeratosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
